Cheshire
Senior Member (Voting Rights)
Against pandemic research exceptionalism
Alex John London, Jonathan Kimmelman
https://science.sciencemag.org/content/early/2020/04/22/science.abc1731
Alex John London, Jonathan Kimmelman
The global outbreak of coronavirus disease 2019 (COVID-19) has seen a deluge of clinical studies, with hundreds registered on clinicaltrials.gov. But a palpable sense of urgency and a lingering concern that “in critical situations, large randomized controlled trials are not always feasible or ethical” (1) perpetuate the perception that, when it comes to the rigors of science, crisis situations demand exceptions to high standards for quality.
The perception that core methodological components of high-quality research are dispensable is underpinned by three problematic assumptions. The first is that some evidence now, even if flawed, seems preferable to expending greater resources on more-demanding studies whose benefits only materialize later. Because the window for learning in pandemics is often short, the need to “balance scientific rigor against speed” seems inevitable (3).
The problem with this view is that challenges that rigorous methods address do not disappear in the face of urgent need. Small studies that build on basic science and preclinical research in early phases of drug development routinely generate signals of promise that are not confirmed in subsequent trials. Even when new drugs are established to be safe and effective, rarely are their benefits so massive that they can be detected in small, open-label, nonrandomized trials.
https://science.sciencemag.org/content/early/2020/04/22/science.abc1731